FLCN and Birt-Hogg-Dube syndrome: In addition, FLCN mutations and loss of its mRNA expression have been observed in various types of sporadic tumors including colorectal cancer, endometrial carcinoma, gastric cancer, and other types of tumors developed in BHD patients [8, 15–27], which further suggests that FLCN is a universal cancer suppressor.